Dyne therapeutics ipo
WebSep 17, 2024 · Amid a parade of upsized biotech IPOs this year, Dyne Therapeutics in Waltham made its debut with a $233 million fundraise — more than double what it said it was hoping to bring in when it first ... WebSep 17, 2024 · IPOs. Waltham, Massachusetts-based Dyne Therapeutics, Inc. priced its upsized initial public offering of 12.253 million shares at $19 versus the estimated price …
Dyne therapeutics ipo
Did you know?
WebAug 26, 2024 · Wednesday’s spinout was prompted by a massive $1.5-plus billion buyout of Tizona by Gilead, announced earlier this month. That agreement gave Gilead 49.9% ownership of ... WebIPO Pro - "The Ultimate Resource for IPOs" Don't risk buying another IPO without IPO Pro. Get your FREE TRIAL now. Start My 1-Week Trial. Follow Us. IPO ETFs. US IPO ETF; …
WebMar 20, 2024 · Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically … WebAug 26, 2024 · BioNTech signs UK government pact to deliver cancer therapies to 100k patients by 2024. Jan 6, 2024 12:29pm.
WebSep 1, 2024 · Dyne Therapeutics (DYN) aims to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The … WebApr 11, 2024 · Dyne Therapeutics has a 52-week low of $4.30 and a 52-week high of $15.63. Dyne Therapeutics ( NASDAQ:DYN - Get Rating ) last issued its quarterly earnings data on Thursday, March 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10.
WebMay 14, 2024 · WALTHAM, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, is presenting new preclinical data from its myotonic dystrophy type 1 (DM1) program …
WebSep 21, 2024 · Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral ... northlanders collected editionsWebMar 14, 2024 · 天眼查为您提供Dyne Therapeutics Inc.的企业信息查询服务，查询Dyne Therapeutics Inc.工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营风险、公司发展状况、公司财务状况、公司股东法人高管、商标、融资、专利、法律诉讼等Dyne Therapeutics Inc.企业信用信息，想了解Dyne Therapeutics Inc.怎么样，就 ... how to say please fruit in spanishWebSep 17, 2024 · Dyne Therapeutics raised $233 million in an initial public offering of 12.3 million shares of its common stock at $19.00 per share. ... 40 percent of the money raised by drug developers in IPOs in 2024. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including programs in the rare genetic wasting diseases myotonic ... northlander rileyWebSep 17, 2024 · Dyne Therapeutics’ IPO and CureDuchenne’s timely funding is an exemplary model of the CureDuchenne venture philanthropy approach. The CureDuchenne Ventures investment made at a critical time in March 2024 helped Dyne de-risk the science and establish proof-of-concept. They were able to keep working, … northlanders coversWebApr 4, 2024 · Ticker Symbol: DYN: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $19.00: CIK Code: 0001379895: CUSIP Number: … how to say please help me in spanishWebSep 17, 2024 · Waltham, Massachusetts-based Dyne Therapeutics, Inc. priced its upsized initial public offering of 12.253 million shares at $19 versus the estimated price range of $16 and $18, to generate gross ... how to say please in bulgarianWebApr 12, 2024 · Since the IPO on September 17, 2024, Dyne Therapeutics, Inc.'s market cap has decreased from $790.90M to $480.56M, a decrease of -39.24%. That is a compound annual growth rate of -17.66%. northlanders book 2